Navigation Links
Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
Date:6/11/2008

Epilepsy Growth of 14%

Fiscal 2009 Revenue Guidance

HOUSTON, June 11 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced results for the fourth quarter, and fiscal year, ended April 25, 2008.

Key quarterly highlights

Key results for the fourth quarter of fiscal 2008 compared to the fourth quarter of fiscal 2007 included:

-- Net sales of $33.9 million, an 8% increase from $31.4 million.

-- Net earnings of $2.9 million, including $1.3 million in insurance

recoveries and $0.4 million in state tax credits, compared with a net

loss of $10.8 million.

-- Earnings per diluted share of $0.11 cents, including $0.07 in credits

from insurance recoveries and state tax credits, compared with a loss

of $0.42 cents per share.

-- Unit sales attributable to the epilepsy indication increased globally

by an estimated 18%, with US unit sales increasing by an estimated 20%.

Net sales

Net sales for fiscal 2008 were $121.2 million, compared to $131.0 million in fiscal 2007. Net product sales in fiscal 2008 attributable to the epilepsy indication were $115.3 million, an increase of $13.9 million, or 14% over fiscal 2007, while sales attributable to the depression indication declined by $24.1 million to $5.4 million from $29.5 million in fiscal 2007.

U.S. net product sales in fiscal 2008 declined to $94.4 million, compared with $111.1 million in fiscal 2007, due to the continued reduction in the number of VNS Therapy(TM) Systems attributable to treatment-resistant depression ("TRD"), following both the preliminary and final non-coverage determinations by the Centers for Medicare and Medicaid Services in February 2007 and May 2007, respectively; however, net sales attributable to the epilepsy indication increased by approximately 10% over the prior year.

International net sales increased by 3
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
2. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
5. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
6. Rosetta Genomics Reports First Quarter 2008 Financial Results
7. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
8. Advance Nanotech Reports First Quarter 2008 Financial Results
9. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
10. Senetek PLC Reports First Quarter 2008 Financial Results
11. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... 180 List of Outstanding Issues (LOI) from the European ... (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 ... investigational drug candidate being evaluated for weight loss. ... time point were adequately addressed by the Company based ...
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... Immunology Summit-2014 will be ... scientists in the field, which includes prominent personalities ... Western Reserve University School of Medicine, USA, who ... “The effects of recombinant human IL-6 and recombinant ... Biragyn, a Senior investigator at National Institute on ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... 8, 2010 Shrink Nanotechnologies, Inc. ("Shrink") (OTC ... nanotechnology company developing products and licensing opportunities in ... and biotechnology research and development tools businesses, announced ... development and manufacturing agreement with EV Group, a ...
... properties, carbon nanotubes are attractive building blocks ... logic devices, and memory elements. However, ... of individual carbon nanotubes and the nanotube-devices, ... commercial use. Now, researchers at Northwestern ...
... Calif., Dec. 7, 2010 California-based StemCyte, Inc. ... www.StemCyte.com , a comprehensive resource on cord blood ... an effort to provide the most comprehensive source ... StemCyte,s new website includes extensive information for customers, ...
Cached Biology Technology:Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 2Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 3Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 4Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 5Using new materials to make more reliable nanoelectromechanical systems 2StemCyte Launches New Website 2
(Date:7/30/2014)... massive collection of 20-million-year-old amber found in the Dominican ... is yielding fresh insights into ancient tropical insects and ... fully curated, a task that will take many years, ... in the world, the researchers report. , Perhaps ... a pygmy locust, a tiny grasshopper the size of ...
(Date:7/30/2014)... use of iodine-125 (125I) in cancer treatment has ... root ganglia are critical for neural transmission between ... Zhang and colleagues from Institute of Radiation Medicine, ... 125I could be implanted into rat dorsal root ... 125I seeds with different radioactivity (0, 14.8, 29.6 ...
(Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... NEW YORK (July 24, 2009) -- A large attack on ... than a million people, necessitating their treatment with powerful antibiotics. ... to be effective, quick detection and treatment are essential, and ... ill people. The results of a computer simulation study ...
... GALVESTON, Texas Researchers at the University of Texas ... to gain weight while using depot medroxyprogesterone acetate, more commonly ... dispel the myth that all women who use DMPA will ... DMPA users whose weight increased by 5 percent within ...
... Union for the Conservation of Nature (IUCN),s Red List ... of species around the planet, and according to these ... endangered. However, research carried out recently by Jos Luis ... scientific protocol designed to identify threatened plants and animals. ...
Cached Biology News:Early detection and quick response are key to defense against anthrax attack 2UTMB study identifies women at risk of gaining excessive weight with injectable birth control 2Red List overlooks island species 2Red List overlooks island species 3
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... Amplification Kit, 100 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
Biology Products: